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Abstract
Since the beginning of the year 2020, the SARS-CoV-2 coronavirus has spread globally at a tremendous pace. Studies 
on the prevalence of SARS-CoV-2 antibodies in the population help estimate the number of people that have already 
been infected. They also allow an estimate of the number of undetected infections i.e. infections that do not appear in 
data on officially reported cases. The interpretation of study results needs to consider bias from selective sampling and 
the diagnostic test properties. To promote networking and co-operation between scientists, the Robert Koch Institute 
has compiled an overview of the seroepidemiological studies conducted in Germany on its website, which is regularly 
updated. The RKI conducts searches, for example of press releases, study registry entries or preprint server publications, 
and contacts the lead investigators of these studies. Of the 40 studies contacted so far, 24 have already provided 
information (as of 25.06.2020). We can differentiate between studies of the general population, of selected population 
groups such as healthcare workers, or of ongoing cohorts. This article provides an overview of such studies from Germany, 
but also of selected international studies. A special focus is set on studies of children and adolescents, which are now 
of particular interest due to the planned reopening of childcare facilities and schools.
  SEROEPIDEMIOLOGICAL STUDIES · ANTIBODIES · SARS-COV-2 · SEROPREVALENCE · INFECTIOUS DISEASE EPIDEMIOLOGY 
1. Introduction
COVID-19 has spread globally at a tremendous pace, and 
both the disease and the virus that causes it – the novel 
coronavirus SARS-CoV-2 – are the target of intensive 
research efforts. Seroepidemiological studies are an impor-
tant area of research, in particular population-based stud-
ies on the prevalence of SARS-CoV-2 antibodies (seropreva-
lence) in the population or in population groups [1, 2]. 
Serological studies provide insight into the fraction of 
people that have already had the infection, including unde-
tected infections (dark figure). This helps assess the 
demand for healthcare, analyse influencing factors for 
symptomatic and asymptomatic courses [3], identify par-
ticularly affected population groups, and determine the 
infection mortality rate (lethality). Moreover, the results are 
highly important to manage infection control measures 
and evaluate non-pharmacological interventions. The 
detection of antibodies does not equate to immunity [4, 5] 
(Info box 1). However, seroprevalence in the population 
does allow an estimate of how far we are from potential 
herd immunity.
With its Unity Studies, the World Health Organization 
(WHO), at an early stage, presented a protocol for conduct-
ing population-based SARS-CoV-2 antibody studies, and 
many studies worldwide are based on this protocol [6]. 
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include manuscripts uploaded to preprint servers (medRxiv, 
bioRxiv, arXiv, ChemRxiv, preprints.org, ResearchSquare, 
and Social Science Research Network (SSRN)) prior to for-
mal peer review. The defined search terms in the title of 
publications were ‘SARS-CoV-2’ AND ‘sero OR antibod OR 
immune OR immunity OR immunology OR fatality rate OR 
population-based OR cohort study OR dried blood OR test 
strategy’. Reports and communications from the WHO, 
the European Centre for Disease Prevention and Control 
(ECDC) and the Center for Disease Control and Prevention 
(CDC) as well as study registries (German Clinical Trials 
Register, ClinicalTrials.gov) were searched and media cov-
erage was also monitored.
2.2 Differentiation of seroepidemiological studies by 
methodology
The results of seroepidemiological studies can only be eval-
uated if differences in methodology are taken into account. 
To assess the influence of bias, information on the sample 
is particularly relevant, as it allows an estimate of how well 
the sample represents the analysed population group. The 
validity of results depends, furthermore, on the type of anti-
body tests used, laboratory analytical procedures, thresh-
old values for a positive result, as well as the time point 
and method of blood sample collection. Finally, the trans-
parency of methods and results is decisive for the evalua-
tion of the results [7]. Ideally, this information is included 
in the study protocol and based on the quality and trans-
parency standards of reporting guidelines for observation-
al studies, of which a version adapted for seroepidemio-
logical studies is also available [8].
The primary objectives are to determine seroprevalence by 
sex and age group, and estimate the fraction of asympto-
matic, pre-symptomatic or subclinical infections in the 
general population. The protocol serves as a framework for 
selecting study populations, determining the study design 
and study duration, as well as specimens, and includes a 
short questionnaire for minimum information from partic-
ipants. It should be adapted to national conditions, such 
as availability of resources and laboratory capacities. The 
protocol has been designed to allow data to be collected 
quickly and systematically and exchanged in a format that 
facilitates aggregation, tabulation and analysis worldwide.
In Germany and internationally, antibody studies are 
being conducted or are planned, and some analyses have 
already concluded. This article provides a brief overview 
of the highly dynamic current state of study with a par-
ticular focus on Germany: what are the most important 
methodological aspects for the evaluation of seroepide-
miological studies? What results are already available? 
Which studies are currently collecting data? In addition, 
the initial results of international seroepidemiological 




To date, there are only few peer-reviewed publications of 
seroepidemiological studies on SARS-CoV-2 in the litera-
ture databases (PubMed and Embase). This applies in par-
ticular to studies from Germany, many of which have begun 
only very recently. The search was therefore expanded to 
Info box 1:  
SARS-CoV-2 antibodies
  Specific IgG-SARS-CoV-2 antibodies indicate a 
past infection.
  Not all infected persons produce antibodies 
to the same extent.
  It is still unclear how long antibodies remain 
detectable [10, 11, 19].
Immunity
  Antibodies indicate an immunological reaction 
to SARS-CoV-2.
  A positive antibody test does not guarantee 
immunity, a negative antibody test does not 
exclude immunity [9].
According to current knowledge, the seropreva-
lence of antibodies at population level is the 
best indicator of how close a population is to 
achieving potential herd immunity.
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[13–16] (Info box 2). Online calculators, illustrative calcu-
lation examples and decision trees for the interpretation 
of test results highlight these correlations, but are not pre-
sented in more detail here [13, 17, 18]. In addition to anti-
body tests, many seroepidemiological studies also include 
tests for acute infections (direct detection of the virus in a 
patient’s oropharyngeal and nasopharyngeal swab, gener-
ally based on polymerase chain reaction (PCR) tests). 
Currently, population based estimates combining the total 
number of those with a positive PCR test and those with a 
positive antibody test are considered to provide the best 
available approximation to the total number of persons 
infected with SARS-CoV-2.
3. Seroepidemiological studies from Germany
A number of studies are currently being planned and con-
ducted in Germany to determine SARS-CoV-2 seropreva-
lence. These studies include both cross-sectional as well 
as longitudinal studies with study populations that are 
highly diverse locally and regionally. To gain a more com-
plete picture of overall SARS-CoV-2 infections in Germany, 
the Robert Koch Institute (RKI) has compiled a regularly 
updated overview of seroepidemiological studies in Ger-
many on its website (www.rki.de/covid-19-serostudies- 
germany). The information is provided by the lead inves-
tigators of studies who were contacted following the 
searches described in Chapter 2.1. As of 25 June 2020, the 
RKI had contacted 40 studies. This article is based on the 
information already received from 24 of these studies. 
Information on further studies can be provided to the RKI 
through a contact form on the RKI website. Detailed study 
The probability of detecting people who have already 
had the disease varies and depends on the sampling frame, 
the target population and response rate (participation rate), 
and does not provide a complete picture of infections in 
the general population. In particular, samples with volun-
tary participants and those that achieve a low response 
rate can produce selection bias. Particularly when compar-
ing groups it is important to assess sampling probabilities 
of participants, for example in household samples where 
there are several participants per household.
Regarding the types of antibody tests, a number of 
methodological aspects need to be taken into account [9]. 
In seroprevalence studies mainly immunoglobulin G (IgG) 
antibodies are measured, and to a lesser extent addition-
ally IgA and IgM antibodies. While in most patients with a 
symptomatic COVID-19 infection viral ribonucleic acid 
(RNA) can be detected directly by oropharyngeal and naso-
pharyngeal swabs (in a patient’s throat or nose) a couple 
of days before the patient develops first symptoms, or 
within the first week after symptoms appear, IgM and IgG 
antibody tests become positive only with the beginning of 
the second week after symptoms first occur [10, 11]. Anti-
body tests can be semi-quantitative, quantitative (antibody 
titer) or qualitative. If possible, positive test results should 
be followed by a second test to confirm the initial result 
[12]. Generally, these will test for neutralising antibodies 
(neutralisation test) and use cell cultures to test whether 
infectious viruses are blocked by antibodies in the serum 
being tested. The analysis of antibody test results has to 
take into account in particular the correct administration 
of tests, sensitivity and specificity, as well as the so-called 
pre-test probability (prevalence of SARS-CoV-2 infection) 
Info box 2:  
SARS-CoV-2 antibody tests
[13, 14, 16, 18–20]
Sensitivity indicates how accurately the test 
detects individuals with SARS-CoV-2 specific 
antibodies.
Specificity indicates how accurately the test 
detects individuals who do not have SARS-
CoV-2 specific antibodies.
Overview of sensitivity and specificity of 
SARS-CoV-2 antibody tests 
For example
  from the Foundation for Innovative New 
Diagnostics (FIND) [21],
  on the websites of the EU Commission [22], 
  from the Federal Institute for Drugs and 
Medical Devices (BfArM) regarding data on 
the officially registered tests in Germany [23].
False positives
  Proportion depends on the specificity of tests 
and of pre-test probability (prevalence).
  A high proportion of false positives is possible 
when the pre-test probability is low (low preva-
lence).
  Illustrative examples for calculations are avail-
able here [13, 20, 24]. 
Pre-test probability for a positive result
  Corresponds to the prevalence in the popula-
tion when tested without specific cause
  Is higher for testing due to symptoms or con-
tact with an infected person.
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an infection hot spot in Germany. Based on the data from 
over 900 ELISA IgG (positive or marginal positive) results, 
complemented by PCR testing, the authors conclude that 
15.5% of inhabitants have been infected with SARS-CoV-2. 
Further key results are that 22.2% of these were asympto-
protocols were published for three of the studies on the 
list; seven studies were registered in the German Clinical 
Trials Register. At the time of publication, there was one 
peer reviewed and published scientific report [25] and two 
preprint papers [26, 27].
The study protocols describe various recruitment pro-
cedures: complete surveys of sub-populations, random 
samples based on population registries, random route 
household samples, and, also, non-probability convenience 
samples from that part of the population that is close at 
hand with diverse recruitment approaches. Semi-quantita-
tive procedures based on enzyme-linked immunosorbent 
assay (ELISA), quantitative immunofluorescence tests and 
luciferase immunoprecipitation tests (LIPS assay) were 
used. Apparently, only one survey so far plans to use a rapid 
test kit (lateral flow assay). To confirm positive antibody 
test results some studies use neutralisation assays.
Figure 1 shows a map of Germany indicating where 
seroepidemiological studies are currently being conducted, 
based on answers to inquiries in preparation of the RKI 
website as of 25 June 2020.
3.1 Studies of the general population
13 seroepidemiological studies with samples from the gen-
eral population have so far been identified and presented 
on the website: three from local hot spots and ten from 
larger cities or regions.
The Gangelt municipality seroprevalence study con-
ducted by the University of Bonn in the district of Heins-
berg, North Rhine-Westphalia, was the first population 
study to provide results on SARS-CoV-2 seroprevalence for 
Setting
    General population
    Cohort study
    Selected population sub-groups
Figure 1
Seroepidemiological studies in Germany, 
results of the Robert Koch Institute query 
(as of 25 June 2020)
Source: Own diagram
Seroepidemiological studies 
provide information about 
the number of people in a 
population that have already 
been infected, including 
previously undetected  
infections.
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determine local levels of immunity in representative 
samples and to investigate regional differences and time 
trends. The study began in early July in the Reutlingen 
district and, over the coming months, will be expanded to 
include seven further districts [30].
Further studies have been conducted in cities. The 
prospec tive COVID-19 cohort Munich study (KoCo19), con-
ducted by the Ludwig Maximilian University (LMU), has 
completed the first cross-sectional examination of 3,003 
randomly selected Munich households. The results are 
expected for the end of July and the study will be continued 
longitudinally [31, 32]. 
Two studies are conducted in Halle (‘COVID-19 
Antikörperstatus Halle/Saale’ and ‘Bevölkerungsbasierte 
Forschungsplattform für COVID-19 Epidemie’), one in Stutt-
gart (‘Ausbreitung des neuen Coronavirus (SARS-CoV-2) 
und die gesundheitlichen Folgen’) [33]. The COVID-19 study 
in Neustadt am Rennsteig, together with a study focused 
on mothers with children under ten years of age in Rostock 
[34] and a study of pregnant women in the Franken region 
co-ordinated at the Friedrich-Alexander Universität Erlangen- 
Nürnberg [35], represent further studies of the – mainly – 
adult population at local and regional levels.
Further larger-scale studies have been announced. 
A Germany-wide seroepidemiological study (‘CORONA- 
MONITORING bundesweit’) by the RKI together with the 
German Institute for Economic Research (DIW) plans to 
use the existing infrastructure of the DIW’s Socio-Economic 
Panel (SOEP) and conduct questionnaire-based interviews 
with the 30,000 SOEP participants. In addition, PCR test-
ing and IgG antibody testing is planned with self-adminis-
tered swabs and kits for blood sampling.
matic infections, as well as that the number of those 
infected had previously been underestimated (80% of infec-
tions had not been officially registered, i.e. the 15.5% sero-
prevalence was approximately five times higher than preva-
lence calculated according to the number of registered 
cases). For early April, an infection fatality rate of 0.36% 
was calculated [27]. The results of the Gangelt study and 
of the upcoming hot spot studies are not representative of 
Germany as a whole.
A further hot spot study was begun in June 2020 in the 
district of Tirschenreuth, Bavaria (TiKoCo, ‘Seroprävalenz 
und -inzidenz Studie im Landkreis Tirschenreuth’), and is 
designed as a repeated cross-sectional survey [28].
The RKI is locally conducting the study ‘CORONA- 
MONITORING lokal’ [29] in four municipalities that have 
been particularly affected by the pandemic. Data is being 
collected through direct tests for a SARS-CoV-2 infection 
(PCR) as well as through testing for IgG antibodies against 
the virus validated by neutralisation tests. The aims are to 
estimate seroprevalence, the proportion of previously 
undetected cases and the proportion of asymptomatic 
infections in order to understand the actual distribution of 
infections in the population. Additional objectives are to 
determine factors associated with a symptomatic or asymp-
tomatic course, sequelae and the different dynamics of 
transmission. In May 2020, a study in the Kupferzell munic-
ipality (Hohenlohe district) was begun and followed in June 
by a study in the Bad Feilnbach municipality (Rosenheim 
district). In each of the four locations, 2,000 randomly 
selected adults are tested [29].
Moreover, the Helmholtz Centre for Infection Research 
is also conducting regional hot spot studies. The aim is to 
Sampling design and test 
types can considerably  
influence the results.
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in a very short time using the then available antibody tests. 
A group of researchers from six renowned international uni-
versities has compiled and regularly updates and presents 
on a ‘dashboard’ a summary of international studies. This 
includes tables that describe the methodologies in detail, 
important results and links to reports and/or publications 
[38]. Furthermore, the first 23 studies that were identified 
(as of 1 May 2020), were critically assessed and summa-
rized in a systematic rapid review published as a preprint 
article in order to rapidly provide the available evidence. The 
substantial methodological heterogeneity of these early 
studies was highlighted, in particular with regard to types 
of tests, sampling procedures and case numbers [39]. For 
some studies, only media reports were initially available, 
and in some cases preliminary results became known before 
the study design was published. This was criticised in the 
media, including via social media channels [40]. 
A more recent compilation of European studies was 
published in the ECDC Rapid Risk Assessment on 11 June 
2020 [41]. Most of the regional studies of the general pop-
ulation or of blood donors show seroprevalences of one-
digit [39, 41–43]. Very severely affected regions such as 
the Ischgl municipality in Tirol and the Italian town of 
Bergamo showed a considerably higher seroprevalence 
in the population (42.4% in Ischgl and 57% in Bergamo) 
[44, 45].
Related to risk factors such as working in the health-
care sector in highly affected regions, seroprevalences of 
around 33% have been reported for New York City and 
Bergamo [45, 46]. In more severely affected regions, sig-
nificant social differences were found [47, 48]. At this point 
in time, even higher prevalences need critical methodo-
3.2 Studies of selected population sub-groups
Rapidly, an increasing number of studies is also being con-
ducted for selected population groups, for example health-
care workers, employees and people living in care homes, 
or among patients hospitalized for non-COVID-related 
reasons. Studies of hospital staff in Munich, Reinbek, Han-
nover and Fulda have been conducted (complete surveys 
in Munich and Reinbek). A study from Bremen focused on 
public sector employees. 
Blood donor specimens selected by a standardised pro-
cedure offer a relatively low-threshold access for seroepide-
miological studies. Since April 2020, a study conducted 
by the RKI in cooperation with blood donation services 
(SeBluCo) aims to analyse 5,100 blood donor specimens 
every two weeks from 29 testing regions across Germany to 
assess the spread of the virus over time. Blood donors rep-
resent a good proxy for the healthy general adult population.
Some studies have used established cohorts from 
longitudinal surveys to gain study participants, such as the 
Rhineland study [36], the COVID-19 module of the 
Hamburg City Health Study and the Fr1da-COVID19 study. 
Such an approach is also possible for the German National 
Cohort, which has already begun interviewing participants 
[37]. The detailed information already available for cohort 
study participants is particularly appropriate to analyse the 
risk factors for an infection or certain disease courses.
4. Seroepidemiological studies in other countries
Seroepidemiological studies have been initiated in many 
countries, beginning in March 2020 increasing from April 
Over 40 seroepidemiological 
studies had been started in 
numerous settings and 
based on diverse  
methodologies in Germany 
by the end of June 2020.
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5. Seroepidemiological studies in children
Compared to adults, children with SARS-CoV-2 infection 
are more frequently asymptomatic or have only mild symp-
toms. For this reason, acute SARS-CoV-2 infections are less 
frequently detected through direct virus tests in children 
[59–62]. Seroepidemiological studies in children are there-
fore particularly important, because they can determine – 
without having to rely on the presence of symptoms – 
whether a person has been infected with SARS-CoV-2. In 
particular with regard to the reopening of childcare facili-
ties and schools, there is currently a great need for valid 
data on children and adolescents’ SARS-CoV-2 antibody 
status, ideally as a trend over time.
In Germany, several seroepidemiological studies based 
on various study designs are being conducted in children. 
One such study involving 1- to 10-year-old children is being 
conducted in Baden-Württemberg (convenience sample). 
Interim results based on the examination of 2,466 par-
ent-child pairs showed a 0.6% (7/1,120) seroprevalence for 
1- to 5-year-old children, a 0.9% (12/1,346) seroprevalence 
for 6- to 10-year-old children and 1.8% (45/2,466) for par-
ents [63]. Further studies of the general population that 
include children are conducted, for example in Stuttgart 
(population registry sample ≥5 years) and the KoCo19 
cohort study in Munich (random route household sample). 
In the Ruhr region, the Corkid study will determine the anti-
body status of 3,000 children and adolescents aged under 
18 during routine medical check-ups [64].
Antibody studies conducted in selected population 
groups include the CORONA study with children from 
schools in Leipzig, Dresden and Zwickau, grades one to 
logical review, for example when studies in hot spots are 
conducted with a small number of voluntary participants 
[49] or when an outbreak at a school is later serologically 
analysed [50].
From May 2020, large national seroprevalence stud-
ies have been announced by several countries, for exam-
ple by the USA [51], Italy [52], Spain and the United 
Kingdom [53]. Already available results from Spain for 
the second wave involving 63,564 participants from 
52 regions show an average seroprevalence of 5.2% with 
important regional differences up to a seroprevalence of 
14.7% [54]. As an intermediate result, the United King-
dom has reported a seroprevalence of 5% or higher, and 
17% in London [53].
More recent findings indicate that SARS-CoV-2 began 
to spread outside of Asia as early as January 2020 [55, 56]. 
This also holds true for some parts of the African conti-
nent. The majority of African countries are supposedly in 
an early stage of the pandemic with increasing case num-
bers. However, in some countries respiratory infections 
have increased [57]. Due to the limited public health and 
surveillance capacities of many countries in the region, 
an undetected spread of COVID-19 even before April 2020 
would seem possible. In this context, determining sub- 
national seroprevalences in African but also South Amer-
ican populations could contribute to developing national 
and regional COVID-19 containment strategies (for a first 
study from Brazil, see [58]). Within the framework of 
existing projects, the RKI currently supports a number of 
countries, with a focus on the African continent, in pre-
paring and implementing seroepidemiological studies, 
for example in Malawi and Nigeria.
Data on SARS-CoV-2  
infections in children are 
needed in the context of 
childcare facilities and 
schools.
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Sweden kept the majority of its schools and its childcare 
facilities open during the pandemic [68].
6. Conclusion
In summary, a large number of seroepidemiological stud-
ies on SARS-CoV-2 in Germany and internationally have 
been initiated in order to determine urgent questions con-
cerning the seroprevalence in specific settings, regions and 
population groups. Due to the considerable psychosocial, 
economic and societal costs of a general lockdown, there 
is considerable interest in understanding the regionally 
differentiated dynamics of infections, also against the back-
drop of measures that have already been taken. The initial 
(preliminary) results thereby consistently highlight that 
thus far no country has managed to achieve anything close 
to herd immunity [69]. 
The criticisms of some of these early studies, as well as 
the accelerated and, to a certain degree, oversimplified 
reporting, have created a broader understanding of the 
possibilities and limits of seroepidemiological studies and 
the importance of study methodologies. Methodological 
developments are already visible in the update of the WHO 
protocol for population-based serological studies [12], as 
well as the international efforts towards standardisation 
and reporting [38, 39]. A large number of further regional 
seroepidemological studies would have to be questioned 
if they were conducted only in order to answer the question 
of achieving local herd immunity at this point. Further 
research questions for seroepidemiological studies there-
fore appear all the more important, for example concern-
ing the dynamic with which the disease spreads, the extent 
eight [65]. A time series study conducted in 14 large pae-
diatric clinics from across Germany is recruiting 0- to 
18-year-old patients [66]. Tests for SARS-CoV-2 antibodies 
among children are also being conducted in the already 
established Fr1da cohort study (2- to 10-year-old children) 
in Bavaria, a children’s cohort for the early detection of 
type 1 diabetes [67]. A further study in the form of a co- 
operation project between the German Youth Institute 
(DJI) and the RKI has also begun (Corona-KiTa study). The 
study focuses on children in preschool childcare facilities 
and aims to examine how transitioning from restricted 
access to childcare during lockdown to gradual reopening 
of facilities is related to an increase in infections among 
children, staff and parents.
Internationally, Switzerland and Sweden have provided 
initial seroepidemiological results in children. In the can-
ton of Geneva, the population representative SERO-
CoV-POP study was conducted, which involved randomly 
selected participants from the respondents of an annual 
health survey and their household members (≥5 years). 
After five of the planned twelve weekly serum surveys 
(6 April – 9 May 2020), the SARS-CoV-2 seroprevalence for 
5- to 9-year-olds (n=123) was 0.8% and 9.6% for 10- to 
19-year-olds (n=332). In comparison, the corresponding 
prevalence for 20- to 49-year-olds (n=1,096) was 9.9% [42]. 
Interim results from a Swedish study based on residual 
serum samples (serum samples collected for other analy-
ses) from outpatient care showed seroprevalences of 7.5% 
for 0- to 19-year-olds, 6.5% for 20- to 64-year-olds and 2.9% 
for the age group 65 years and older during the survey 
period between 11 and 17 May 2020. These results are par-
ticularly important because, unlike most other countries, 
A more comprehensive 
picture can be gained from a 
joint appraisal of current and 
future studies.
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and patterns of underdetection of infections compared to 
reported cases, the proportion of asymptomatically infected 
individuals by age group, the risk and protective factors for 
an infection, how antibodies develop over time, as well as 
the long-term health impacts of infections. 
While taking into account the heterogeneity of study 
designs and samples, as well as laboratory analysis proce-
dures, the results from the seroepidemiological studies in 
numerous regions and settings can increasingly be used 
for modelling the course of the pandemic [14, 70]. It is 
important to recognise, at the high pace dictated by the 
pandemic, when study results apply only locally or in a 
specific time period and when they can be generalised. The 
joint effort of different studies and the development of 
common research questions will be important to gain a 
better understanding of the pandemic dynamics and to 
provide an epidemiological database that can help to 
design effective and proportionate interventions.
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